Alnylam Pharmaceuticals Cancer Drugs Clinical Pipeline Insight

Publish Date:- Oct-2016      No Of Pages (37)

Electronic Access - Single User License $500 Buy Now
CD-ROM Mail Delivery $800Buy Now
Hard Copy Mail Delivery $800 Buy Now
Electronic Access - Multi-User License $1000 Buy Now


“Alnylam Pharmaceuticals - Cancer Drugs Clinical Pipeline Insight” offers in depth insight on ongoing clinical trials for the cancer drugs developed by Alnylam. This report highlights various clinical and non-clinical parameters involved in the development of cancer drugs in clinical pipeline. Currently there are “9” cancer drugs in clinical pipeline.

The report includes all the relevant information with respect to development of cancer drugs in the clinical pipeline. Report helps the reader in identifying various data and information points like Drug Class, Mechanism of Action, Granted Orphan Designation, Fast Track Development Status, Clinical Introduction, Drug Formulation/ Route, Owner/License, Multiple Development Phase of particular drug and Patent Information.

“Alnylam Pharmaceuticals - Cancer Drugs Clinical Pipeline Insight” report is comprehensively researched and well drafted encyclopedia which helps to analyze and understand the various parameters involved in the clinical development of cancer drugs by the respective company. This research publication also helps in identifying the long term investment and partnering opportunity for the various stake holders of the pharmaceutical industry.


“Alnylam Pharmaceuticals - Cancer Drugs Clinical Pipeline Insight” offers in depth insight on ongoing clinical trials for the cancer drugs developed by Alnylam. This report highlights various clinical and non-clinical parameters involved in the development of cancer drugs in clinical pipeline. Currently there are “9” cancer drugs in clinical pipeline.

The report includes all the relevant information with respect to development of cancer drugs in the clinical pipeline. Report helps the reader in identifying various data and information points like Drug Class, Mechanism of Action, Granted Orphan Designation, Fast Track Development Status, Clinical Introduction, Drug Formulation/ Route, Owner/License, Multiple Development Phase of particular drug and Patent Information.

“Alnylam Pharmaceuticals - Cancer Drugs Clinical Pipeline Insight” report is comprehensively researched and well drafted encyclopedia which helps to analyze and understand the various parameters involved in the clinical development of cancer drugs by the respective company. This research publication also helps in identifying the long term investment and partnering opportunity for the various stake holders of the pharmaceutical industry.

1. Alnylam Pharmaceuticals

  1.1 Business Overview

  1.2 Alnylam Pharmaceuticals Cancer Pipeline Overview

 

2. Alnylam Pharmaceuticals Cancer Drugs in Research Phase

  2.1 RNAi Therapeutics - Alnylam/Arrowhead Pharmaceuticals

  2.2 RNAi Therapeutics - Alnylam/Takeda

 

3. Alnylam Pharmaceuticals Cancer Drugs in Preclinical Phase

  3.1 RNAi Therapeutics – Arbutus

  3.2 Cancer Therapeutics - Molecular Templates

  3.3 RNAi Cancer Therapeutics – Calando

  3.4 Systemic RNAi Therapeutics - Alnylam/Arbutus Biopharma

 

4. Alnylam Pharmaceuticals Cancer Drugs in Phase-I

  4.1 MT 3724

  4.2 ALN VSP

 

5. Alnylam Pharmaceuticals Cancer Drugs in Phase-I/II

  5.1 TKM PLK1

 

6. No Development Reported in Cancer Drugs in Clinical Pipeline

  6.1 RNA Interference-Based Technology – Alnylam

  6.2 RNAi Therapeutics - Alnylam/University of California San Francisco

 

7. Discontinued in Cancer Drugs in Clinical Pipeline

  7.1 RPI 4610

  7.2 Anti-HER2 Ribozyme - Elan/Sirna

  7.3 RNAi Therapeutics - Sirna Therapeutics/Eli Lilly


Figure 1-1: Alnylam Pharmaceuticals Cancer Pipeline by Phase (%)

Figure 1-2: Alnylam Pharmaceuticals Cancer Pipeline by Phase (Number)

Figure 1-3: Alnylam Pharmaceuticals Cancer Drugs Discontinued & No Development Reported in Clinical Pipeline by Phase (%)

Figure 1-4: Alnylam Pharmaceuticals Cancer Drugs Discontinued & No Development Reported in Clinical Pipeline by Phase (Number)